Carcinoembryonic Antigen Market - Top Companies and Manufacturers

Companies Dominating the Carcinoembryonic Antigen Landscape

The carcinoembryonic antigen market is positioned to expand during the forecast period. Key players in the market are investing in research & development to introduce advanced CEA testing solutions. Additionally, companies are expanding product portfolios to include a broader range of cancer biomarkers to cater to the rising demand for cancer diagnostics. Furthermore, collaborations between healthcare providers, research institutions, and the government are poised to create a sustained demand for CEA kits.

Here are some key players in the carcinoembryonic antigen market:

Hoffman-La Roche Ltd
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Merck KGaA
Creative Diagnostics
Aviva Systems Biology Corporation
Omega Diagnostics Ltd.
Novartis
Thermo Fischer Scientific Ltd.
Diazyme Laboratories Inc
AdvaCare Pharma

Browse Key Market Insights with Data Illustration:

Carcinoembryonic Antigen Market Size & Share, Forecast Report 2037

In the News

In March 2024, A2 Biotherapeutics, Inc. announced that the U.S. FDA granted orphan drug status to A2B530 as a treatment for patients who have colorectal cancer. A2B530 consists of an activator that targets CEA and a blocker that targets HLA-A 02.
In May 2024, Tempus announced the clinical launch of its MRD testing portfolio. The portfolio features both a tumor-naïve assay and a tumor-informed assay that is designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response

Frequently Asked Questions (FAQ)

The carcinoembryonic antigen market was valued at USD 2.34 billion in 2024 and is poised to expand at a CAGR of 6.5% during the forecast period from 2025 to 2037.

The carcinoembryonic antigen market was valued at USD 2.34 billion in 2024 and is expected to reach USD 5.31 billion in 2037 at a CAGR of 6.5% during the forecast period from 2025 to 2037.

The major players in the market are Hoffman-La Roche Ltd, Merck KGaA, Creative Diagnostics, Aviva Systems Biology Corporation, Omega Diagnostics Ltd., Novartis, Thermo Fischer Scientific Ltd., Diazyme Laboratories Inc, AdvaCare Pharma, and others.

The gastrointestinal cancer segment of the carcinoembryonic antigen market is poised to dominate the sector with a 43.4% revenue share by the end of the forecast period. The segment’s growth is owed to the increasing utilization of CEA tests in detecting colorectal cancer.

North America is projected to dominate the global market with a 39.5% revenue share by the end of the forecast period. The regional market’s growth is owed to the growing awareness on CEA monitoring in the region along with the rising demand for CEA home testing kits

Carcinoembryonic Antigen Market - Top Companies and Manufacturers

Companies Dominating the Carcinoembryonic Antigen Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the carcinoembryonic antigen market?

What is the outlook for the carcinoembryonic antigen market?

Who are the major players dominating the carcinoembryonic antigen market?

Which product segment will capture the significant market share for the carcinoembryonic antigen sector by 2037?

Which region will provide more business opportunities for the growth of the carcinoembryonic antigen market in the future?